Molecule Information

General Information of the Molecule (ID: Mol01225)

Name	Long non-protein coding RNA 518 (LINC00518) ,Homo sapiens
Synonyms	LINC00518 Click to Show/Hide
Molecule Type	LncRNA
Gene Name	WIT-1, WIT1, WT1-AS1, WT1AS
Gene ID	221718
Location	chr6:10429255-10435015[-]
Ensembl ID	ENSG00000183674
HGNC ID	HGNC:28626
*Click to Show/Hide the Complete Species Lineage*
Kingdom: Metazoa Phylum: Chordata Class: Mammalia Order: Primates Family: Hominidae Genus: Homo Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Drug

Approved Drug(s)

3 drug(s) in total

Click to Show/Hide the Full List of Drugs

Doxorubicin

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Epigenetic Alteration of DNA, RNA or Protein (EADR)			Click to Show/Hide
Disease Class: Breast cancer				[1]
Sensitive Disease	Breast cancer [ICD-11: 2C60.3]			Disease Info
Sensitive Drug	Doxorubicin			Drug Info
Molecule Alteration	Expression		Down-regulation
Experimental Note	Revealed Based on the Cell Line Data
Cell Pathway Regulation	Cell apoptosis		Activation	hsa04210
	Cell viability		Inhibition	hsa05200
	miR199a/MRP1 signaling pathway		Regulation	hsa05206
In Vitro Model	MCF-7 cells	Breast	Homo sapiens (Human)	CVCL_0031
	MCF-7/ADR cells	Breast	Homo sapiens (Human)	CVCL_1452
In Vivo Model	Nude mouse xenograft model			Mus musculus
Experiment for Molecule Alteration	RT-qPCR
Experiment for Drug Resistance	XTT assay; Flow cytometry assay; Caspase 9 activity assay
Mechanism Description	Linc00518 downregulation reduced MDR by upregulating miR-199a which downregulates MRP1 in breast cancer.

Paclitaxel

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Epigenetic Alteration of DNA, RNA or Protein (EADR)			Click to Show/Hide
Disease Class: Prostate cancer				[2]
Resistant Disease	Prostate cancer [ICD-11: 2C82.0]			Disease Info
Resistant Drug	Paclitaxel			Drug Info
Molecule Alteration	Expression		Up-regulation
Experimental Note	Revealed Based on the Cell Line Data
In Vitro Model	DU-145 cells	Prostate	Homo sapiens (Human)	CVCL_0105
	LNCaP cells	Prostate	Homo sapiens (Human)	CVCL_0395
	PC3 cells	Prostate	Homo sapiens (Human)	CVCL_0035
	RWPE-1 cells	Prostate	Homo sapiens (Human)	CVCL_3791
Experiment for Molecule Alteration	RT-PCR
Experiment for Drug Resistance	MTT assay
Mechanism Description	Long non-coding RNA Linc00518 Can enhance GATA6 expression by suppressing miR-216b-5p expression to promotes paclitaxel resistance in the human prostate cancer.

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Epigenetic Alteration of DNA, RNA or Protein (EADR)			Click to Show/Hide
Disease Class: Breast cancer				[1]
Sensitive Disease	Breast cancer [ICD-11: 2C60.3]			Disease Info
Sensitive Drug	Paclitaxel			Drug Info
Molecule Alteration	Expression		Down-regulation
Experimental Note	Revealed Based on the Cell Line Data
Cell Pathway Regulation	Cell apoptosis		Activation	hsa04210
	Cell viability		Inhibition	hsa05200
	miR199a/MRP1 signaling pathway		Regulation	hsa05206
In Vitro Model	MCF-7 cells	Breast	Homo sapiens (Human)	CVCL_0031
	MCF-7/ADR cells	Breast	Homo sapiens (Human)	CVCL_1452
In Vivo Model	Nude mouse xenograft model			Mus musculus
Experiment for Molecule Alteration	RT-qPCR
Experiment for Drug Resistance	XTT assay; Flow cytometry assay; Caspase 9 activity assay
Mechanism Description	Linc00518 downregulation reduced MDR by upregulating miR-199a which downregulates MRP1 in breast cancer.

Vincristine

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Epigenetic Alteration of DNA, RNA or Protein (EADR)			Click to Show/Hide
Disease Class: Breast cancer				[1]
Sensitive Disease	Breast cancer [ICD-11: 2C60.3]			Disease Info
Sensitive Drug	Vincristine			Drug Info
Molecule Alteration	Expression		Down-regulation
Experimental Note	Revealed Based on the Cell Line Data
Cell Pathway Regulation	Cell apoptosis		Activation	hsa04210
	Cell viability		Inhibition	hsa05200
	miR199a/MRP1 signaling pathway		Regulation	hsa05206
In Vitro Model	MCF-7 cells	Breast	Homo sapiens (Human)	CVCL_0031
	MCF-7/ADR cells	Breast	Homo sapiens (Human)	CVCL_1452
In Vivo Model	Nude mouse xenograft model			Mus musculus
Experiment for Molecule Alteration	RT-qPCR
Experiment for Drug Resistance	XTT assay; Flow cytometry assay; Caspase 9 activity assay
Mechanism Description	Linc00518 downregulation reduced MDR by upregulating miR-199a which downregulates MRP1 in breast cancer.

Disease- and Tissue-specific Abundances of This Molecule

ICD Disease Classification 02

Click to Show/Hide the Resistance Disease of This Class

Prostate cancer [ICD-11: 2C82]

Click to Show/Hide

Differential expression of molecule in resistant diseases
The Studied Tissue	Prostate
The Specified Disease	Prostate adenocarcinoma
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.73E-03; Fold-change: 2.33E-01
Molecule expression in the diseased tissue of patients Molecule expression in the normal tissue of healthy individuals
Disease-specific Molecule Abundances		Click to View the Clearer Original Diagram
Download Molecule expression barchart for all samples Download Molecule expression data of patients in the disease section of the tissue Download Molecule expression data in the tissue of healthy individual

Tissue-specific Molecule Abundances in Healthy Individuals

Click to Show/Hide the Molecule Abundances


Download the Tissue-Specific Variation(s) Profile

References

Ref 1	Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer. Cell Physiol Biochem. 2018;48(1):16-28. doi: 10.1159/000491659. Epub 2018 Jul 12.
Ref 2	Long non-coding RNA Linc00518 promotes paclitaxel resistance of the human prostate cancer by sequestering miR-216b-5p. Biol Cell. 2019 Feb;111(2):39-50. doi: 10.1111/boc.201800054. Epub 2018 Dec 7.